Peter Cicala
Vermögen: - $ am 31.07.2026
Vermögen: - $ am 31.07.2026
Peter Cicala is the founder of Boundless Bio, Inc. (2019).
Mr. Cicala is an Independent Director at Ernexa Therapeutics, Inc. since 2024.
Formerly, Chief Intellectual Property Counsel at Intercept Pharmaceuticals, Inc. (2020-2021) and Chief Patent Counsel at Celgene Corp.
(2014-2019).
Education includes an undergraduate degree from Fairleigh Dickinson University and a graduate degree from Seton Hall University School of Law.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 07.05.2026 | 0 ( -.--% ) | - $ | 31.07.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ERNEXA THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 12.02.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2021 |
| CELGENE | Corporate Officer/Principal | 01.11.2019 |
| BOUNDLESS BIO, INC. | Gründer | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of chronic fibrotic and metabolic diseases | Health Technology |
Fairleigh Dickinson University
Fairleigh Dickinson University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seton Hall University School of Law
Seton Hall University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boundless Bio, Inc.
Boundless Bio, Inc. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that develops cancer therapeutics | Health Technology |
Eterna Therapeutics, Inc.
Eterna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops cytokine-based drugs for the treatment of cancer | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen